Evaluating aspirin's effectiveness in patients with chronic coronary syndromes who can't undergo revascularization

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the efficacy and safety of aspirin in patients diagnosed with chronic coronary syndromes who are not candidates for revascularization procedures. It is a multicenter, randomized, open-label trial that will compare outcomes between patients receiving aspirin and those not receiving it. The study addresses a gap in current knowledge regarding the use of aspirin for secondary prevention in this specific patient population, as previous research has primarily focused on other groups. By evaluating the impact of aspirin on cardiovascular events and safety in these patients, the study seeks to provide valuable insights into its potential benefits.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with chronic coronary syndromes with ≧50% diameter stenosis in one or more major coronary vessels/major branches on coronary CT or coronary angiography but not eligible for coronary revascularization
* Patients for whom consent can be obtained

Exclusion Criteria:

* Patients with history of acute coronary syndromes (ACS)
* Patients with history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)
* Patients with left main trunk stenosis (≥50%)
* Patients for whom aspirin administration is mandatory
* Patients undergoing antithrombotic therapy other than aspirin
* Patients with atrial fibrillation
* Patients with history of stroke within six months
* Patients scheduled for major surgical procedures that will require aspirin discontinuation
* Patients with contraindication of aspirin
* Patients expected to have a prognosis of 1 year or less due to comorbidities
* Women of child-bearing potential or women who have a positive pregnancy test at enrolment or randomization
* Patients who are judged by attending physicians to be inappropriate to participate in this study

Where it's running

• Kyoto University Hospital
  Kyoto, Japan Recruiting

Study contacts

• Principal investigator: Takeshi Kimura, MD, PhD — Kyoto University, Graduate School of Medicine
• Study coordinator: Takeshi Kimura, MD, PhD
• Email: taketaka@kuhp.kyoto-u.ac.jp
• Phone: +81-75-751-4255

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• QFR-guided virtual stenting to optimize PCI before the procedure

  We’re testing whether using QFR-based virtual stenting before PCI can improve heart-procedure outcomes compared with standard angiography planning in adults with coronary artery disease.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07635407

• LONG NAGOMI PMCF: follow-up of the Ultimaster Nagomi stent in long coronary artery lesions

  This project tests the Ultimaster Nagomi drug-eluting stent in adults undergoing PCI for long coronary lesions to collect real-world safety and effectiveness data.

  Recruiting at 10 sites Fundación EPIC · Cabueñes and 9 other locations · NCT07399002

• Using transthoracic echocardiography to improve care for stable chest pain

  This project will test whether adding transthoracic echocardiography (TTE) helps doctors make better decisions and lowers major heart problems in adults with stable chest pain suspected to be from coronary artery disease.

  Recruiting Tianjin Chest Hospital · Tianjin · NCT07063147

• Coronary CT angiography versus standard follow-up after stent placement for high-risk patients

  This trial will test whether using coronary CT angiography instead of usual follow-up care helps people at high risk after stent placement stay healthier.

  Recruiting at 2 sites Samsung Medical Center · Bucheon-si and 21 other locations · NCT07009418

• Ultrathin strut stent for patients on blood thinners

  This study is testing a new type of stent for patients on blood thinners to see if it can safely reduce the time they need to take additional blood-thinning medication after heart procedures.

  Recruiting at 13 sites Fundación EPIC · Albacete and 12 other locations · NCT06863155

• Essential Pro paclitaxel‑eluting coronary balloon post-market follow-up (rEPIC04E-HK)

  This project will follow people with coronary artery disease treated with the Essential Pro paclitaxel‑eluting coronary balloon to see if the device is safe and works well in routine care.

  Recruiting Fundación EPIC · Lai Chi Kok · NCT06631157

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.